Retatrutide and Semaglutide are both incretin-based therapies, primarily investigated for their roles in metabolic disease management, particularly obesity and type 2 diabetes. Retatrutide, described as a multi-agonist, has shown significant weight loss and improvements in glycemic and lipid parameters in meta-analyses, suggesting a broad impact on cardiometabolic health. Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight loss and cardiovascular benefits, including a noted reduction in MACE for obese patients, and is also explored for its potential in managing type 2 diabetes. Both peptides aim to improve patient health outcomes by addressing obesity and related metabolic disorders.
| Retatrutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist, gip agonist, glucagon agonist | glp 1 agonist |
| Studies in corpus | 134 | 691 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | review · 49 preclinical animal · 11 meta analysis · 25 other · 21 rct · 23 in vitro · 1 | rct · 67 meta analysis · 9 review · 23 in vitro · 4 cohort · 16 preclinical animal · 4 case report · 3 case series · 3 other · 26 |
| Studies with explicit sample size | 2 | 42 |
| Head-to-head studies in corpus | 4 | |
Studies in our corpus that mention both Retatrutide and Semaglutide — the gold-standard direct comparison evidence.
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated by newer agents like tirzepatide and sem…
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new benchmark for pharmacotherapy in this high…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer a more potent and potentially safer alte…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of dual and triple incretin agonists offer…
No direct head-to-head trials in our corpus. Indirect comparison only. Retatrutide is characterized as a dual or triple incretin agonist, suggesting a multi-target approach that may contribute to its noted efficacy in weight loss and comprehensive cardiometabolic health, as highlighted in reviews. Meta-analyses on Retatrutide specifically point to a robust evidence base for its broad therapeutic potential in obesity and related metabolic disorders, including significant improvements in metabolic parameters among kidney transplant recipients. Semaglutide, primarily a GLP-1 receptor agonist, has established itself with demonstrated cardiovascular benefits, including a 20% reduction in MACE for obese patients. Studies on Semaglutide also explore different formulations, with oral semaglutide 25 mg achieving exposure similar to subcutaneous 2.4 mg and leading to greater weight loss in simulated studies. While both show promise for weight loss, Semaglutide has also been investigated for potential ocular risks like non-arteritic anterior ischemic optic neuropathy, and its efficacy in Parkinson's disease has been explored, though current evidence does not consistently support it for motor or non-motor symptoms.
Looking for vendor-level purity, endotoxin, and HPLC data on Retatrutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.